Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vitamin D and Cocaine Administration
NCT04826133 · Yale University · EARLY_PHASE1 · terminated · last registry update 2023-08-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Could not obtain additional funding to continue the research.” | – | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VDR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-09-21Phase 3 first posted: Inozyme Pharma, INZ-701 + Control Arm (Conventional Therapy) (NCT06046820)
- 2023-06-26Phase 3 first posted: LEO Pharma, LEO 90100 + Daivobet® ointment (NCT05919082)
- 2023-05-01Phase 3 first posted: University of Rochester, Placebo Administration (NCT05838716)
- 2023-03-14Results posted on the registry: Brigham and Women's Hospital, omega-3 fatty acids (fish oil) (NCT01696435)
- 2023-01-11Phase 3 first posted: Calcilytix Therapeutics, Inc., a BridgeBio company, Encaleret (NCT05680818)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision